Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.50 |
| ▸ | GSK3B | P49841 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27777502 | 0.84 | MAPT (0.55) | MAPTKDM4EPTPN1KMT2ANPC1 | |
| SCHEMBL399793 | 0.80 | RAB9A (0.61) | MAPTKDM4EPTPN1KMT2ANPC1 | |
| SCHEMBL3502303 | 0.78 | MAPT (0.62) | MAPTKDM4EKMT2ANPC1RAB9A | |
| SCHEMBL1028065 | 0.78 | MAPT (0.62) | MAPTKDM4EPTPN1KMT2ANPC1 | |
| SCHEMBL1021624 | 0.78 | MAPT (0.55) | MAPTKDM4EPTPN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL5008268 | 0.77 | MAPT (0.61) | MAPTKDM4EPTPN1KMT2ANPC1 | |
| SCHEMBL19900671 | 0.76 | KMT2A (0.78) | MAPTKDM4EKMT2ANPC1RAB9A | |
| SCHEMBL28750524 | 0.74 | MAPT (0.58) | MAPTKDM4EKMT2ANPC1RAB9A | |
| SCHEMBL8574570 | 0.74 | MAPT (0.55) | MAPTKDM4EPTPN1KMT2ANPC1 | |
| SCHEMBL8575256 | 0.74 | MAPT (0.55) | MAPTKDM4EPTPN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1286988-A2 | 1-(H-1,2,4-TRIAZOL-1-YL)BUTAN-2-OL DERIVATIVES | Basilea Pharmaceutica AG (CH) | 2003-03-05 | — | — | EP | disclosed |
| US-20010047017-A1 | Azole derivatives | HOFFMANN-LA ROCHE, INC. | 2001-11-29 | — | — | US | disclosed |
| US-6319933-B1 | 1-(1H-1,2,4-triazol-1-yl)butan-2-ol derivatives; fungicides | BASILEA PHARMACEUTICA AG (CH) | 2001-11-20 | — | — | US | disclosed |
| WO-2001079196-A2 | 1-(H-1,2,4-TRIAZOL-1-YL)BUTAN-2-OL DERIVATIVES | BASILEA PHARMACEUTICA AG (CH) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047017-A1 | Azole derivatives | ERG28, CYP51A1, CYP3A5 | MAPT 2247/4885KDM4E 1105/4885PTPN1 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.